A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
Study Details
Study Description
Brief Summary
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Primary Objective:
To assess the association between the status of NPi drop from baseline (prior to CAR T-cell infusion) to the lowest NPi post Axi-cel (CD19 CAR-T cell) infusion and the status of immune effector cell-associated neurotoxicity onset within 10 days post CD19 CAR-T cell infusion.
Secondary Objective:
To evaluate the largest absolute difference in NPi between two eyes (∆ NPi) and assess its association with severity of clinical symptoms as measured by Immune Effector Cell Encephalopathy (ICE) and or radiographic / EEG findings
Exploratory Objective:
To assess the feasibility and safety of a pupillometer use in patient treated with Axi-cel therapy.
Study Design
Outcome Measures
Primary Outcome Measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [Through study completion; an average of 1 year.]
Eligibility Criteria
Criteria
Inclusion Criteria:
To be considered eligible for study participation, patient will satisfy all relevant inclusion criteria and none of the exclusion criteria.
Inclusion Criteria:
-
Ages Eligible for Study: 18 Years and above (Adult, Older Adult)
-
Sexes Eligible for Study: All
-
Patient with histologically proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
Patients who have already been administered CAR-T cell therapy.
-
The patient who is unwilling or unable to comply with the requirements of the study including being able to be assessed with pupillometer
-
Patient has a condition which places him at an unacceptable risk as determined by the investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
Investigators
- Principal Investigator: Ranjit Nair, MD, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2023-0176
- NCI-2023-09804